Frontiers in Cardiovascular Medicine (Jul 2024)

Implications of anemia in patients undergoing PCI with Impella-support: insights from the PROTECT III study

  • Batla Falah,
  • Björn Redfors,
  • Björn Redfors,
  • Björn Redfors,
  • Duzhi Zhao,
  • Aditya S. Bharadwaj,
  • Mir Babar Basir,
  • Julia B. Thompson,
  • Rajan A. G. Patel,
  • Michael J. Schonning,
  • Arsalan Abu-Much,
  • Yiran Zhang,
  • Wayne B. Batchelor,
  • Cindy L. Grines,
  • William W. O’Neill

DOI
https://doi.org/10.3389/fcvm.2024.1429900
Journal volume & issue
Vol. 11

Abstract

Read online

BackgroundAnemia is prevalent among patients with cardiovascular disease and is associated with adverse outcomes. However, data regarding the impact of anemia in high-risk percutaneous coronary intervention (HRPCI) are limited.ObjectivesThis study aimed to evaluate the impact of anemia in patients undergoing Impella-supported HRPCI in the PROTECT III study.MethodsPatients undergoing Impella-supported HRPCI in the multicenter PROTECT III study were assessed for anemia based on baseline hemoglobin levels according to World Health Organization criteria. Patients were stratified into three groups, namely, no anemia, mild anemia, and moderate or severe anemia. Major adverse cardiovascular and cerebrovascular events (MACCE: all-cause death, myocardial infarction, stroke/transient ischemic attack, and repeat revascularization) at 30 and 90 days, and major bleeding events were compared across groups.ResultsOf 1,071 patients with baseline hemoglobin data, 37.9% had no anemia, 43.4% had mild anemia, and 18.7% had moderate or severe anemia. Anemic patients were older and more likely to have comorbidities. Anemia was associated with higher MACCE rates at 30 days (moderate to severe, 12.3%; mild, 9.8%; no anemia, 5.4%; p = 0.02) and at 90 days (moderate to severe, 18.7%; mild, 14.6%; none, 8.3%; p = 0.004). These differences persisted after adjustment for potential confounders at 30 and 90 days, and sensitivity analysis excluding dialysis showed similar results. Major bleeding at 30 days was also higher in anemic patients (5.5% vs. 1.2%, p = 0.002).ConclusionBaseline anemia in Impella-supported HRPCI is common and independently associated with MACCE and major bleeding, emphasizing its significance as a prognostic factor. Specific management strategies to reduce anemia-associated MACCE risk after HRPCI should be examined.Clinical Trial InformationTrial Name: The Global cVAD Study (cVAD)ClinicalTrial.gov Identifier: NCT04136392URL: https://clinicaltrials.gov/ct2/show/NCT04136392?term=cvad&draw=2&rank=2

Keywords